Drug Profile
Syk kinase silencer - ZaBeCor Pharmaceuticals
Alternative Names: ExcellairLatest Information Update: 28 Jul 2015
Price :
$50
*
At a glance
- Originator University of Pennsylvania
- Developer ZaBeCor Pharmaceuticals
- Class Anti-inflammatories; Antiasthmatics; Small interfering RNA
- Mechanism of Action RNA interference; Syk kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Inflammation
Most Recent Events
- 28 Jul 2015 Discontinued - Phase-II for Asthma in USA (Inhalation)
- 28 Jul 2015 Discontinued - Preclinical for Inflammation in USA (unspecified route)
- 24 May 2006 Preclinical trials in Asthma in USA (Inhalation)